Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by DryBoneson Jun 30, 2018 10:19pm
97 Views
Post# 28256568

RE:RE:Bio and Barfalony planting daisies in manure.

RE:RE:Bio and Barfalony planting daisies in manure.Gee Barcey, since I hadn't heard from you in a while I was worried you put me on ignore.  Hah,
No such luck! 

Sorry I haven't the time or inclination to read your lengthy missive.  Try paragraphs, or point form or saying nothing at all rather than repeating yourself. Your posting and denials just seems to trigger more questions and the more explanations on behalf of PLI seem even more questionable.

Today the price of failing to deliver is .520, not more, not less.  To correct the problem managment could deliver on time and stop blaming the FDA.  

There are reasons for rejection, either something they failed to do, or because the clinical trials that they designed never established what they had hoped for. It seems to me that the FDA took their word for what they claimed in the trial design.  It is PLI that makes the submissions.  Do they have any credibility left with the FDA?  

Credibility with the FDA  will become an issue if it is not already. Thank gawd they hired a new firm to advise on the FDA, so maybe the problem will be corrected.  Trouble is, I think they are now framing issues with the intention of redirecting their clinical focus again.  This will mean more delays.  It's happened before.  It is part of the reason for lack of trust.

BTW I never used the word "lying" or "lie" 
Bullboard Posts